157 related articles for article (PubMed ID: 28716665)
1. Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils.
Christensen HB; Gloriam DE; Pedersen DS; Cowland JB; Borregaard N; Bräuner-Osborne H
J Pharmacol Toxicol Methods; 2017 Nov; 88(Pt 1):72-78. PubMed ID: 28716665
[TBL] [Abstract][Full Text] [Related]
2. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1.
Cevik-Aras H; Kalderén C; Jenmalm Jensen A; Oprea T; Dahlgren C; Forsman H
Biochem Pharmacol; 2012 Jun; 83(12):1655-62. PubMed ID: 22410002
[TBL] [Abstract][Full Text] [Related]
3. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
4. FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils.
Gabl M; Holdfeldt A; Sundqvist M; Lomei J; Dahlgren C; Forsman H
Biochem Pharmacol; 2017 Dec; 145():114-122. PubMed ID: 28855087
[TBL] [Abstract][Full Text] [Related]
5. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Cheng N; Ye RD; Quinn MT
Biochem Pharmacol; 2014 Dec; 92(4):627-41. PubMed ID: 25450672
[TBL] [Abstract][Full Text] [Related]
7. The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop.
Forsman H; Bylund J; Oprea TI; Karlsson A; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2013 Aug; 1833(8):1914-23. PubMed ID: 23562731
[TBL] [Abstract][Full Text] [Related]
8. The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists.
Karlsson J; Fu H; Boulay F; Bylund J; Dahlgren C
Biochem Pharmacol; 2006 May; 71(10):1488-96. PubMed ID: 16549058
[TBL] [Abstract][Full Text] [Related]
9. The PAR4-derived pepducin P4Pal
Holdfeldt A; Lind S; Hesse C; Dahlgren C; Forsman H
Biochem Pharmacol; 2020 Oct; 180():114143. PubMed ID: 32653592
[TBL] [Abstract][Full Text] [Related]
10. Functional selective FPR1 signaling in favor of an activation of the neutrophil superoxide generating NOX2 complex.
Lind S; Dahlgren C; Holmdahl R; Olofsson P; Forsman H
J Leukoc Biol; 2021 Jun; 109(6):1105-1120. PubMed ID: 33040403
[TBL] [Abstract][Full Text] [Related]
11. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
Lind S; Sundqvist M; Holmdahl R; Dahlgren C; Forsman H; Olofsson P
Biochem Pharmacol; 2019 Aug; 166():163-173. PubMed ID: 31085160
[TBL] [Abstract][Full Text] [Related]
12. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
13. A neutrophil inhibitory pepducin derived from FPR1 expected to target FPR1 signaling hijacks the closely related FPR2 instead.
Winther M; Gabl M; Welin A; Dahlgren C; Forsman H
FEBS Lett; 2015 Jul; 589(15):1832-9. PubMed ID: 26071379
[TBL] [Abstract][Full Text] [Related]
14. PKC-delta controls the fMLF-induced overproduction of superoxide by neutrophils.
Matron C; Chakravarti A; Allaeys I; Poubelle PE
Free Radic Biol Med; 2010 Jan; 48(2):207-15. PubMed ID: 19854263
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed g protein-coupled receptors.
Lee PH; Gao A; van Staden C; Ly J; Salon J; Xu A; Fang Y; Verkleeren R
Assay Drug Dev Technol; 2008 Feb; 6(1):83-94. PubMed ID: 18336088
[TBL] [Abstract][Full Text] [Related]
16. Propofol inhibits superoxide production, elastase release, and chemotaxis in formyl peptide-activated human neutrophils by blocking formyl peptide receptor 1.
Yang SC; Chung PJ; Ho CM; Kuo CY; Hung MF; Huang YT; Chang WY; Chang YW; Chan KH; Hwang TL
J Immunol; 2013 Jun; 190(12):6511-9. PubMed ID: 23670191
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies.
Ruzza C; Ferrari F; Guerrini R; Marzola E; Preti D; Reinscheid RK; Calo G
Pharmacol Res Perspect; 2018 Dec; 6(6):e00445. PubMed ID: 30534379
[TBL] [Abstract][Full Text] [Related]
18. The anionic amphiphile SDS is an antagonist for the human neutrophil formyl peptide receptor 1.
Thorén FB; Karlsson J; Dahlgren C; Forsman H
Biochem Pharmacol; 2010 Aug; 80(3):389-95. PubMed ID: 20394736
[TBL] [Abstract][Full Text] [Related]
19. What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4?
Forsman H; Önnheim K; Andreasson E; Dahlgren C
Scand J Immunol; 2011 Sep; 74(3):227-234. PubMed ID: 21535079
[TBL] [Abstract][Full Text] [Related]
20. Activation of formyl peptide receptor 2 by WKYMVm enhances emergency granulopoiesis through phospholipase C activity.
Kim HS; Park MY; Lee SK; Park JS; Lee HY; Bae YS
BMB Rep; 2018 Aug; 51(8):418-423. PubMed ID: 30021674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
